aTyr Pharma Announces Second Quarter 2021 Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
aTyr Pharma (LIFE) Misses Q2 EPS by 13c
August 10, 2021 4:25 PM EDTaTyr Pharma (NASDAQ: LIFE) reported Q2 EPS of ($0.64), $0.13 worse than the analyst estimate of ($0.51).
Cash, cash equivalents and investments as of June 30, 2021 were $44.1 million.
We recently completed the last subject visit in our Phase 1b/2a proof-of-concept study of our lead therapeutic candidate,... More
